Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/27—Growth hormone [GH], i.e. somatotropin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/31—Somatostatins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

• the present invention relates to oral delivery of octreotide in combination with other therapeutic agents for treatment of acromegaly.
• the present invention relates to combination therapy of a subject suffering from acromegaly.
• the method of treatment comprises administration to the subject of a therapeutically effective amount of an oral somatostatin receptor ligand (SRL) e.g. oral octreotide in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a selective estrogen receptor modulator (SERM).
• SRL oral somatostatin receptor ligand
• SERM selective estrogen receptor modulator
• the dopamine agonist is cabergoline or bromocriptine.
• the growth hormone receptor antagonist is pegvisomant.
• the oral SERM is clomiphene e.g. a clomiphene salt such as clomiphene citrate.
• Another aspect of this invention is a unit dosage formulation for oral administration comprising octreotide and a dopamine agonist; in a particular aspect the dopamine agonist is cabergoline.
• Another aspect of this invention is a unit dosage formulation for oral administration comprising octreotide and a SERM; in a particular aspect the SERM is clomiphene e.g. a clomiphene salt such as clomiphene citrate.
• Acromegaly is caused by a benign (non-cancerous) tumor (an adenoma) within the pituitary gland that secretes excess growth hormone (GH), leading to elevated levels of insulin-like growth factor-1 (IGF-1).
• GH growth hormone
• IGF-1 insulin-like growth factor-1
• Drug treatment of acromegaly Currently, several forms of medical therapy are used: Two of these forms of medical therapy are receptor-based, directed at the pituitary adenoma (the somatostatin receptor ligands—SRLs—octreotide, lanreotide and pasireotide which are all given by injection) and the dopamine agonist cabergoline given orally.
• SRLs somatostatin receptor ligands
• GHRA pegvisomant
• SRLs may be given in a “long-acting” formulation (e.g. depot formulation or other slow release formulation) or in a “short-acting” (e.g. immediate release) formulation.
• the “long-acting” formulation is normally given by means of injection at dosing intervals of four weeks, or alternatively at dosing intervals of 3-8 weeks e.g. at 3, 4, 5, 6, 7, or 8 weeks.
• the interval between two injections of long-acting SRLs is termed the dosing interval.
• the “short-acting” formulation is normally a subcutaneous injection given daily (or even two or three times a day or more), or may be given 2, 3, 4, 5, or 6 times per week. SRLs were originally termed somatostatin analogs or agonists.
• SERM selective estrogen receptor modulator
• New potential therapeutic agents for acromegaly are described in Melmed 2015, Nature Reviews Endocrinology, DOI:doi:10.1038/nrendo.2015.196; published online 27 Nov. 2015.
• These therapeutic agents include the investigational SRL named DG3173 administered by i.m. injection every four weeks; the investigational antisense oligonucleotide named ATL1103, which is a GH receptor antagonist (disrupts GH receptor gene expression) and an investigational long-acting SRL based on octreotide bound in liquid crystal matrix named CAM2029.
• SRLs injectable octreotide or injectable lanreotide
• the aim of treatment is to lower the GH and IGF-1 levels to as close to normal as possible and to improve control of symptoms.
• Patients who do not respond to injectable SRL therapy (those in whom GH and IGF-1 levels undergo minimal change) or only partially respond (biochemically) to SRL therapy or patients whose acromegaly symptoms are not adequately controlled are often switched to combination therapy: options include (a) injectable SRL plus dopamine agonist (eg cabergoline or bromocriptine); (b) injectable SRL plus growth hormone receptor antagonist (eg pegvisomant); and (c) injectable SRL plus SERM (e.g. clomiphene).
• injectable SRL plus dopamine agonist eg cabergoline or bromocriptine
• injectable SRL plus growth hormone receptor antagonist eg pegvisomant
• SERM injectable SRL plus SERM
• the current invention includes the treatment of acromegaly by treatment with an oral SRL e.g. octreotide in combination with one or more other therapeutic agents.
• Options include (a) oral SRL plus dopamine agonist e.g. cabergoline or bromocriptine; (b) oral SRL plus growth hormone receptor antagonist e.g. pegvisomant or ATL1103; (c) oral SRL plus a SERM e.g. clomiphene and (d) oral SRL plus injectable SRL.
• the oral SRL may be oral octreotide, lanreotide or pasireotide or an oral formulation of DG3173.
• the injectable SRL may be octreotide (eg Sandostatin®), lanreotide (eg Somatuline® Depot in the US and Somatuline® Autogel elsewhere), pasireotide, DG3173 or CAM2019.
• octreotide eg Sandostatin®
• lanreotide eg Somatuline® Depot in the US and Somatuline® Autogel elsewhere
• pasireotide DG3173 or CAM2019.
• a particular case in which the invention may be used is as follows. It may be used with a na ⁇ ve acromegaly patient who is given oral octreotide in the dosage recommended herein, and thereafter has elevated IGF-1 levels and/or the IGF-1 level has been reduced by 50% of pre-treatment level.
• Dopamine agonist an oral therapeutic agent
• Growth hormone receptor antagonist such as pegvisomant or ATL1103
• clomiphene may be used in combined therapy with oral octreotide instead of dopamine agonist.
• Another particular case in which the invention may be used is as follows. It may be used with a na ⁇ ve acromegaly patient who is given oral dopamine agonist in the dosage recommended herein, and thereafter has elevated IGF-1 levels the IGF-1 level has been reduced by 50% of pre-treatment level. Oral octreotide may be added as combined therapy (i.e. in combination with dopamine agonist). Growth hormone receptor antagonist (such as pegvisomant) may be used initially instead of dopamine agonist.
• Another particular case in which the invention may be used is as follows. It may be used with an acromegaly patient who is already receiving therapy comprising injectable octreotide, lanreotide or pasireotide in combination with dopamine agonist or growth hormone receptor antagonist; the patient switches to oral octreotide instead of injectable octreotide in combination with the dopamine agonist or growth hormone receptor antagonist or SERM.
• the invention may be used in the treatment of patients who switch from parenteral injection to oral, and have elevated IGF-1 levels.
• a dopamine agonist or clomiphene or pegvisomant will be added.
• Oral octreotide therapy in combination with another therapeutic agent as described herein may provide advantages over injectable octreotide combined therapy. These advantages may be better control of IGF-1 and/or hGH levels, or control of IGF-1 and/or hGH levels at lower dosages of medication.
• the invention includes the reduction of one or more symptoms of acromegaly such as joint pain, swelling of extremities, headaches, asthenia, sleep apnea and perspiration i.e. improvement in Acromegaly Index of Severity. Particular symptoms include headache, swelling of extremities, joint pain, sweating and fatigue.
• biochemical control i.e. control of IGF-1 and GH
• some symptoms may persist over the long-term despite SRL therapy.
• Acromegaly symptoms may either occur throughout the dosing interval (the interval between two injections of long-acting SRLs, normally 4 weeks) or recur towards the end of the dosing interval.
• Leading experts e.g. Melmed 2015 April J. Clin.
• Breakthrough acromegaly symptoms are common phenomena.
• a possible intuitive explanation is decline in the pharmacodynamic effects of SRLs towards the end of the dosing interval of the long-acting treatments (see e.g .Melmed, 2015 J. Clin. Endocrine Metab. ibid).
• clinicians may prescribe, in addition to the long-acting SRL, daily subcutaneous (sc) SRL and/or schedule long-acting injections at a frequency of less than every 4 weeks to control breakthrough symptoms towards the end of the dosing interval.
• sc daily subcutaneous
• These additional daily sc injections and/or more frequent long-acting injections may be effective in controlling the breakthrough symptoms, yet significantly increase the physical, emotional, and financial burden of the treatment.
• Another aspect of the invention is the use of oral octreotide administered in addition to long-acting SRLs or other therapies to prevent or treat breakthrough acromegaly symptoms.
• This “rescue therapy” may be given on a regular basis towards the end of the four-week dosing interval or on an “as needed basis” when symptoms such as headache or swelling of extremities or any of the acromegaly symptoms recur.
• Oral formulations of octreotide have been described, for example in co-assigned U.S. Pat. No. 8,329,198 which is hereby incorporated by reference.
• the oral octreotide may be in a capsule or a tablet.
• the current invention which has novel and useful benefits, is an oral formulation of octreotide, in combination with one or more other therapeutic agents.
• One aspect of this invention is a method of treatment of a subject suffering from acromegaly which comprises administration to the subject of a therapeutically effective amount of an oral somatostatin receptor ligand (SRL) in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a 2 nd somatostatin receptor ligand (SRL) and/or a selective estrogen receptor modulator (SERM).
• the oral somatostatin receptor ligand (SRL) is octreotide or lanreotide or pasireotide.
• the oral somatostatin receptor ligand (SRL) is octreotide.
• the level of IGF-1 in the subject is only partially controlled on octreotide alone. In another aspect of this invention the level of IGF-1 in the subject is only partially controlled on dopamine agonist alone.
• the dopamine agonist administered in combination with oral octreotide is cabergoline.
• the dopamine agonist is bromocriptine.
• the growth hormone receptor antagonist is pegvisomant.
• oral octreotide comprises about 5 mg to about 120 mg of octreotide daily, about 40 to about 80 mg of octreotide daily, or about 10 to about 80 mg of octreotide daily, such as 10, 20, 30, 40, 50, 60, 70 or 80 mg daily.
• a particular dosage of oral octreotide is 80 mg daily.
• the daily dose of octreotide may be administered in one or two doses a day e.g. the 80 mg daily dose may be administered in two doses of 40 mg each.
• the administration of cabergoline in combination with oral octreotide comprises about 0.2 to about 5 mg of cabergoline weekly; about 0.4 to about 4 mg of cabergoline weekly, such as 1, 2, 3, 3.5 or 4 mg of cabergoline weekly; or about 0.2 to about 1 mg of cabergoline weekly, such as 0.2, 0.40, 0.6 0.8 or 1.0 mg of cabergoline weekly.
• the administration of cabergoline is bi-weekly, three times weekly or daily.
• the administration of cabergoline is gradually increased from 0.5 mg ⁇ 2 per week for first two weeks, 1 mg ⁇ 2 per week for additional two weeks, followed by 1.5 mg ⁇ 2 per week for additional two weeks reaching a maintenance dose of 1.75 mg ⁇ 2 per week.
• the administration of cabergoline is up-titrated to reach a maintenance dose of 3.0 mg to 3.5 mg weekly.
• a particular aspect of this invention is a method of treating acromegaly in a subject comprising the following steps: administration of oral octreotide with an initial dose of 20 mg BID; receiving information regarding blood levels of IGF-1 and/or clinical symptoms and in response to blood levels of IGF-1 and/or clinical symptoms, evaluating the course of treatment, wherein if blood levels of IGF-1 are normal and/or clinical symptoms are controlled and/or response level (biochemical and symptomatic response) is maintained, maintain oral octreotide dosage at 20 mg BID; and wherein if IGF-1 levels are increased, or in case of symptomatic exacerbation, dosage of oral octreotide may be adjusted to 60 mg daily (40 mg morning+20 mg evening); continuing to receive information regarding blood levels of IGF-1 and/or clinical symptoms, and evaluating the course of treatment (e.g., applying the above algorithm for maintaining or increasing the dose up to 40 mg BID); wherein if the blood levels of IGF-1 and/or clinical symptoms indicate the subject
• the second therapeutic agent is cabergoline, preferably administered up to 3.5 mg/week.
• the cabergoline may be administered twice weekly, preferably with dinner, with a fixed titration algorithm every two weeks, starting with 0.5 mg ⁇ 2/week at the first two weeks, 1 mg ⁇ 2/week for additional two weeks, followed by 1.5 mg ⁇ 2/week, and increase to a maximum of 1.75 mg ⁇ 2/week.
• the daily dose of cabergoline can be up to 0.5 mg/day (3.5 mg/week), or up to 1 mg ⁇ 3/week (3.0 mg/week). If IGF-1 is normal and clinical symptoms are controlled or response level (biochemical and symptomatic response) is maintained, continue combination therapy
• the administration of pegvisomant in combination with oral octreotide comprises about 2 mg to about 60 mg of pegvisomant daily, about 10 to about 20 mg of pegvisomant daily; or about 2 to about 10 mg of pegvisomant daily, such as 2, 4, 6, 8 or 10 mg of pegvisomant daily.
• the pegvisomant may be administered one or twice or three times or four times or five times or six times per week in these daily amounts. In an embodiment the pegvisomant is administered three times per week.
• a particular aspect of this invention is a method of treatment of a subject suffering from acromegaly which comprises administration to the subject a therapeutically effective amount of oral octreotide in combination with a therapeutically effective amount of a SERM.
• the SERM is clomiphene.
• Other SERMs of this invention include tamoxifen and raloxifen.
• the administration of octreotide comprises about 5 mg to about 120 mg of octreotide daily or about 40 to about 100 mg of octreotide daily or 80 mg of octreotide daily.
• the administration of clomiphene comprises 10-200 mg per day or in particular about 50 mg per day. Estrogens may also be used in combination with oral SRLs, in particular for women.
• Another aspect of this invention is a method of treatment of a subject suffering from acromegaly which comprises administration to the subject of a therapeutically effective amount of an oral somatostatin receptor ligand (SRL) in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a 2 nd somatostatin receptor ligand (SRL) and/or a selective estrogen receptor modulator (SERM) wherein the oral somatostatin receptor ligand (SRL) is octreotide or lanreotide or pasireotide and wherein the 2 nd somatostatin receptor ligand (SRL) is a long-acting injectable formulation.
• SRL oral somatostatin receptor ligand
• SRL selective estrogen receptor modulator
• the subject is treated with oral octreotide and with a 2 nd somatostatin receptor ligand (SRL) which is a long-acting injectable formulation, which may be administered every 4 weeks, or every 3-6 weeks or every 3, 4, 5, or 6 weeks.
• SRL 2 nd somatostatin receptor ligand
• the administration of oral octreotide in addition to the long-acting SRL is in order to control breakthrough acromegaly symptoms.
• the administration of oral octreotide comprises about 10 to about 80 mg of octreotide daily, such as 10, 20, 30, 40, 50, 60, 70 or 80 mg daily.
• the octreotide is administered on an “as needed” basis to control breakthrough acromegaly symptoms.
• the octreotide is administered on a regular basis e.g. on a daily basis.
• the octreotide is administered on a daily basis toward the end of the month wherein the long-acting somatostatin receptor ligand was administered.
• the octreotide is administered during the fourth week after the long-acting somatostatin receptor ligand was administered, preferably on a daily basis.
• Another aspect of this invention is a unit dosage formulation for oral administration comprising a SRL and a dopamine agonist; in a particular aspect the SRL is octreotide and in another particular aspect the dopamine agonist is cabergoline.
• this unit dosage formulation comprises 5-120 mg octreotide, in particular 20 mg octreotide.
• this unit dosage formulation comprises 5-120 mg octreotide and 0.01-1.0 mg cabergoline.
• Another aspect of this invention is a unit dosage formulation for oral administration comprising an SRL and a SERM; in a particular aspect the SRL is octreotide; in another particular aspect the SERM is clomiphene.
• the unit dosage formulation comprises 5-120 mg octreotide and clomiphene.
• the unit dosage formulation comprises 5-120 mg octreotide and 5-200 mg clomiphene.
• the unit dosage formulation comprises 20 mg octreotide.
• Another aspect of this invention is a unit dosage formulation for oral administration comprising an SRL and a dopamine agonist and a SERM i.e. three active pharmaceutical ingredients (APIs).
• the SRL is octreotide.
• the dopamine agonist is cabergoline.
• the SERM is clomiphene.
• the dopamine agonist is cabergoline and the SERM is clomiphene.
• Further aspects of this “triple API” unit dosage formulation comprise 5-120 mg octreotide.
• Other aspects of this “triple API” unit dosage formulation comprise 0.01-1.0 mg cabergoline.
• Other aspects of this triple API unit dosage formulation comprise 5-200 mg clomiphene.
• a particular aspect of this triple API unit dosage formulation comprises 5-120 mg octreotide, 0.01-1.0 mg cabergoline and 5-200 mg clomiphene.
• this triple API unit dosage formulation comprises 20 mg octreotide.
• Another aspect of this invention is a method of treatment of a subject suffering from acromegaly which comprises administration to the subject a therapeutically effective amount of an SRL in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor agonist and/or a SERM; in particular aspects the oral SRL is selected from octreotide, lanreotide and pasireotide (SOM-230).
• the dopamine agonist is cabergoline.
• the dopamine agonist is bromocriptine.
• the growth hormone receptor antagonist is pegvisomant.
• SERM is clomiphene.
• Octreotide is a cyclic octapeptide (e.g. a salt such as acetate or chloride) and is an analog (agonist) of the natural hormone somatostatin; it mimics somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon and insulin than the natural hormone.
• the molecular weight of octreotide is 1019.3 (free peptide, C49H66N10010S2).
• Injectable octreotide is sold commercially as Sandostatin® which is a short-acting formulation administered sc and Sandostatin® LAR, which is a long-acting formulation administered by intramuscular (im) injection.
• oral octreotide in the following formulations is disclosed and claimed in co-assigned U.S. Pat. No. 8,329,198; see for example claims 1 - 26 .
• Oral octreotide for clinical trials is provided as an enteric-coated capsule containing 20 mg of octreotide (20 mg calculated as free base), polyvinylpyrrolidone (PVP-12), sodium caprylate, magnesium chloride, polysorbate 80, glyceryl monocaprylate, glyceryl ricaprylate, gelatin, gelatin capsules and Acryl-EZE® (methacrylate).
• the pharmaceutical compositions described herein include incorporation of octreotide as a therapeutic agent within an oral dosage form which is enteric-coated.
• An oral dosage form according to the invention comprises additives or excipients that are suitable for the preparation of the oral dosage form according to the present invention.
• the oral dosage form may comprise tablets or capsules, preferably enteric-coated.
• SRLs are lanreotide (eg Somatuline® Depot in the US and Somatuline Autogel elsewhere) which is a cyclic octapeptide, and pasireotide (Signifor® ; SOM-230) which is a cyclic hexapeptide and is currently approved for 2 nd line therapy and in clinical trials.
• Somatuline® Depot is a long-acting formulation
• Signifor® is a short-acting formulation which may be administered subcutaneously once or twice a day or more.
• Cabergoline tablets contain cabergoline, a dopamine receptor agonist.
• the chemical name for cabergoline is 1-[(6-allylergolin-8 ⁇ -yl)-carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea. Its molecular formula is C26H37N5O2, and its molecular weight is 451.62.
• Pegvisomant (trade name Somavert®) is a growth hormone receptor antagonist.
• Pegvisomant is a protein containing 191 amino acid residues to which several polyethylene glycol polymers have been covalently bound in order to slow clearance from the blood.
• the protein is a modified version of human growth hormone designed to bind to and block the growth hormone receptor. It is manufactured using genetically modified E. coli bacteria.
• the polyethylene glycol polymers are subsequently added chemically. This is a short-acting formulation which is administered by subcutaneous injection given daily (or even two or three times daily or more). It may also be administered or once, twice, three, four, five or six times per week e.g. when used in combination therapy.
• Clomiphene is a selective estrogen receptor modulator (a SERM) i.e. it is a competitive inhibitor of estrogen binding to estrogen receptors (ERs) and has mixed agonist and antagonist activity, depending upon the target tissue. It has several trade names including Androxal®, Clomid® and Omifin®. Chemically, clomiphene is a non-steroidal triphenylethylene derivative. As currently manufactured, clomiphene is a mixture of two geometric isomers, enclomifene (E-clomifene) and zuclomifene (Z-clomifene). These two isomers have been found to contribute to the mixed estrogenic and anti-estrogenic properties of clomiphene. The use of clomiphene in methods of this invention may be in male and female subjects.
• SERM selective estrogen receptor modulator
• Administered “in combination”, as used herein, means that two (or more) different therapeutic agents are delivered to the subject during the course of the subject's affliction with the disorder, e.g., the two or more therapeutic agents are delivered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons.
• the delivery of one therapeutic agent is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent delivery”.
• the delivery of one therapeutic agent ends before the delivery of the other treatment begins. In some embodiments of either case, the therapeutic agents are more effective because of combined administration.
• the second therapeutic agent is more effective, e.g., an equivalent effect is seen with less of the second therapeutic agent, or the second therapeutic agent reduces symptoms to a greater extent, than would be seen if the second therapeutic agent were administered in the absence of the first therapeutic agent, or the analogous situation is seen with the first therapeutic agent.
• delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one therapeutic agent delivered in the absence of the other.
• the effect of the two therapeutic agents can be partially additive, wholly additive, or greater than additive.
• the delivery can be such that an effect of the first therapeutic agent delivered is still detectable when the second is delivered.
• compositions described herein can be administered to a subject i.e., a human or an animal, in order to treat the subject with a pharmacologically or therapeutically effective amount of a therapeutic agent described herein.
• the animal may be a mammal e.g., a mouse, rat, pig, dog horse, cow or sheep.
• the terms “pharmacologically effective amount” or “therapeutically effective amount” or “effective amount” means that amount of a drug or pharmaceutical agent (the therapeutic agent) that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician and/or halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition, or prevents development of the condition.
• treatment refers to therapeutic treatment, wherein the object is to reduce or reverse or prevent the symptoms of a disease or disorder.
• the compounds or compositions disclosed herein are administered prior to onset of the disease or disorder. In some embodiments, the compounds or compositions disclosed herein are during or subsequent to the onset of the disease or disorder.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Endocrinology (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Diabetes (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=56108186

Family Applications (6)

Family Applications After (5)

Country Status (9)

Cited By (7)

Families Citing this family (2)

Citations (2)

Family Cites Families (17)

• 2015
  • 2015-12-10 CA CA2970519A patent/CA2970519A1/en active Pending
  • 2015-12-10 AU AU2015360485A patent/AU2015360485B2/en active Active
  • 2015-12-10 EP EP23206479.0A patent/EP4321213A3/de active Pending
  • 2015-12-10 US US14/965,318 patent/US20160193285A1/en not_active Abandoned
  • 2015-12-10 WO PCT/US2015/065006 patent/WO2016094662A1/en active Application Filing
  • 2015-12-10 EP EP15868039.7A patent/EP3229824A4/de not_active Withdrawn
  • 2015-12-10 MA MA041159A patent/MA41159A/fr unknown
• 2017
  • 2017-06-05 IL IL252689A patent/IL252689B/en unknown
  • 2017-06-12 ZA ZA2017/04026A patent/ZA201704026B/en unknown
• 2018
  • 2018-04-09 HK HK18104622.8A patent/HK1245115A1/zh unknown
  • 2018-05-07 US US15/972,557 patent/US10682387B2/en active Active
• 2020
  • 2020-05-07 US US16/868,958 patent/US20210077569A1/en not_active Abandoned
  • 2020-09-24 AU AU2020239738A patent/AU2020239738A1/en not_active Abandoned
• 2021
  • 2021-08-08 IL IL285440A patent/IL285440A/en unknown
• 2022
  • 2022-07-11 US US17/861,996 patent/US20220339240A1/en not_active Abandoned
• 2023
  • 2023-02-17 US US18/170,886 patent/US20230201302A1/en not_active Abandoned
  • 2023-10-20 US US18/490,985 patent/US20240041973A1/en not_active Abandoned
• 2024
  • 2024-01-25 AU AU2024200465A patent/AU2024200465A1/en active Pending

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events